Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 28 · below the Ichimoku cloud · RSI 33 · MACD below its signal
| 45.50 | 52-week high | +172.29% |
| 41.50 | Previous month high | +148.35% |
| 29.00 | Previous week high | +73.55% |
| 23.80 | Previous month low | +42.43% |
| 20.54 | R3 (classic) | +22.90% |
| 19.70 | R2 (classic) | +17.91% |
| 18.87 | Previous day high | +12.93% |
| 18.21 | R1 (classic) | +8.96% |
| 17.37 | Pivot | +3.97% |
| 16.71 | Price now | |
| 16.54 | Previous day low | −1.02% |
| 16.54 | Previous week low | −1.02% |
| 15.88 | S1 (classic) | −4.99% |
| 15.04 | S2 (classic) | −9.97% |
| 13.55 | S3 (classic) | −18.93% |
| 4.98 | 52-week low | −70.20% |
No member of Congress has disclosed a CUE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $463.6K | 0.00% | 14.69K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 11, 2026 | Ray Sumita J.D.Officer | Sale at price 28.05 per share. | 1.8K | $51.72K |
| Oct 11, 2026 | Lin Shao-LeeChief Executive Officer | Sale at price 27.50 - 28.05 per share. | 11.1K | $305.49K |
| Oct 11, 2026 | Meluzio Michael Vincent CpaOfficer | Sale at price 28.05 per share. | 1.1K | $32.09K |
| Aug 12, 2026 | Lin Shao-LeeChief Executive Officer | Sale at price 26.99 - 29.48 per share. | 58.3K | $1.61M |
| Aug 12, 2026 | Meluzio Michael Vincent CpaOfficer | Sale at price 29.37 - 31.13 per share. | 5.6K | $169.32K |
| Aug 12, 2026 | Ray Sumita J.D.Officer | Sale at price 29.37 - 31.13 per share. | 8.8K | $265.63K |
| Aug 12, 2026 | Ray Sumita J.D.Officer | — | 18.2K | — |
| Aug 12, 2026 | Meluzio Michael Vincent CpaOfficer | — | 13.6K | — |
| Aug 11, 2026 | Lin Shao-LeeChief Executive Officer | — | 109.2K | — |
| Jul 29, 2026 | Ahlers James M.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 25.5K | — |
| Jul 12, 2026 | Borie Dominique Christian M.D., Ph.D.Officer | Stock Award(Grant) at price 0.00 per share. | 31.5K | — |
| Jul 8, 2026 | Ray Sumita J.D.Officer | Stock Award(Grant) at price 0.00 per share. | 54.6K | — |
| Jul 8, 2026 | Lin Shao-LeeChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 327.5K | — |
| Jul 8, 2026 | Camardo Daniel A.Director | Stock Award(Grant) at price 0.00 per share. | 21.8K | — |
| Jul 8, 2026 | Garzone PamelaDirector | Stock Award(Grant) at price 0.00 per share. | 21.8K | — |
| Jul 8, 2026 | Garzone PamelaDirector | Stock Award(Grant) at price 0.00 per share. | 18.9K | — |
| Jul 8, 2026 | Sarraf PashaDirector | Stock Award(Grant) at price 0.00 per share. | 21.8K | — |
| Jul 8, 2026 | Sarraf PashaDirector | Stock Award(Grant) at price 0.00 per share. | 18.4K | — |
| Jul 8, 2026 | Meehan Viola MongDirector | Stock Award(Grant) at price 0.00 per share. | 21.8K | — |
| Jul 8, 2026 | Meluzio Michael Vincent CpaOfficer | Stock Award(Grant) at price 0.00 per share. | 40.9K | — |
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Buy / hold / sell counts
TimeframesDown on the hourly, daily and monthly, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.8 | -16.4 | -17.9 | 113.6 | 48.6 | 44.1 | -15.0 | -4.9 | 1.4 | -35.4 | +82.6% | ||
| 2025 | 33.0 | -15.2 | -25.9 | -17.1 | -15.5 | 6.9 | 10.1 | 3.9 | -7.8 | 6.8 | -18.0 | -51.6 | −72.0% |
| 2024 | 0.0 | -21.4 | -8.9 | 0.5 | -14.2 | -23.9 | -32.7 | -13.4 | 4.7 | 112.7 | -24.2 | -10.7 | −58.7% |
| 2023 | 20.0 | -18.1 | 27.5 | 21.3 | -7.6 | -8.8 | 4.7 | -29.1 | -15.1 | -8.7 | 19.0 | 5.6 | −7.4% |
| 2022 | -34.7 | -21.5 | -15.9 | -18.9 | -2.3 | -35.7 | 9.2 | 8.1 | -24.1 | 19.3 | 45.1 | -26.2 | −74.8% |
| 2021 | 8.2 | 0.5 | -10.4 | -0.6 | 18.2 | -18.8 | -10.6 | 15.1 | 21.5 | -16.2 | 0.4 | -7.7 | −9.6% |
| 2020 | -4.4 | 15.3 | -18.9 | 80.3 | 8.2 | -11.5 | -22.8 | -5.5 | -15.8 | -26.0 | 25.5 | -10.5 | −21.2% |
| 2019 | 8.7 | 25.2 | 20.8 | 9.8 | -2.7 | 8.8 | -7.6 | -1.4 | 2.9 | 1.8 | 38.0 | 34.1 | +237.8% |
| 2018 | 0.0 | -7.3 | -21.4 | 16.0 | -7.4 | -23.6 | 6.2 | -5.9 | -29.9 | -26.2 | 0.4 | −69.0% |